Changeflow GovPing Healthcare & Life Sciences Hemorrhage Prevention Compounds Patent Application
Routine Notice Added Final

Hemorrhage Prevention Compounds Patent Application

Favicon for changeflow.com USPTO Patent Applications - Therapeutics (A61P)
Published
Detected
Email

Summary

Jesus E. VILLAFRANCA, Charles Richard KISSINGER, and Guohong LI filed Application US20260108481A1 on December 12, 2025, for compounds and methods for the prevention and treatment of hemorrhage and vascular instability. The application, which relates to therapeutic compounds potentially induced by thrombolytic and anti-coagulant therapies, was published on April 23, 2026. The invention is classified under CPC codes including A61K 31/167, A61K 38/482, and A61P 7/04.

“Hemorrhage and vascular instability can be induced by thrombolytic and anti-coagulant therapies.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 193 changes logged to date.

What changed

The USPTO published Application US20260108481A1 for compounds and methods of treating hemorrhage and vascular instability. The application names Jesus E. VILLAFRANCA, Charles Richard KISSINGER, and Guohong LI as inventors, with a filing date of December 12, 2025. The published application includes an abstract describing therapeutic methods using the disclosed compounds for subjects in need thereof.

Pharmaceutical manufacturers and drug developers researching hemostatic agents or anti-coagulant reversal therapies may wish to review this published application to assess potential freedom-to-operate considerations or identify potential licensing opportunities. Published patent applications serve as prior art as of the filing date, which may be relevant for competitive intelligence and IP strategy purposes.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

COMPOUNDS FOR PREVENTION AND TREATMENT OF HEMORRHAGE AND VASCULATURE INSTABILITY

Application US20260108481A1 Kind: A1 Apr 23, 2026

Inventors

Jesus E. VILLAFRANCA, Charles Richard KISSINGER, Guohong LI

Abstract

Hemorrhage and vascular instability can be induced by thrombolytic and anti-coagulant therapies. Presented herein, in certain aspects, are methods for the treatment and/or prevention of hemorrhage and vascular instability that comprise administering a compound disclosed herein to a subject in need thereof.

CPC Classifications

A61K 31/167 A61K 38/482 A61P 7/04 A61P 9/10 C12Y 304/21068

Filing Date

2025-12-12

Application No.

19418727

View original document →

Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application filing Therapeutic compound development Hemorrhage treatment research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Regulatory Affairs
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!